![]() |
|
|
Vol. 58, Issue 6, 1536-1545, December 2000
B
Department of Microbiology and Immunology (Z.H.L., H.-H.K.) and Department of Pediatric Dentistry (S.H.L.), Chosun University Dental School, Kwangju, Korea; Research Institute of Medical Sciences, Chonnam University, Kwangju, Korea (K.K.K.); and Immunomodulation Research Center, Ulsan University, Ulsan, Korea (Z.H.L., K.K., H.-H.K.)
| |
Abstract |
|---|
|
|
|---|
Receptor activator of nuclear factor
B (RANK), a lately identified
member of the tumor necrosis factor receptor superfamily, plays
important roles both in osteoclastogenesis and in lymph node
development. Previously, we and others showed that RANK could stimulate
the activity of c-Jun N-terminal kinase (JNK). In this study, we
investigated the mechanism by which RANK activates JNK. We found that
N-terminal deletion mutants of tumor necrosis factor receptor-associated factor 2 and 6 were inhibitory to RANK activation of JNK. The JNK activation by RANK was also reduced by cotransfection of kinase-inactive mutants of apoptosis signal-regulating kinase 1, MAPK/ERK kinase kinase 1, and nuclear factor
B-inducing
kinase. In addition, dominant negative mutants of Rac and Ras decreased the RANK stimulation of JNK activity. Furthermore, we determined whether the RANK engagement of JNK signaling pathways could lead to the
activation of the activator protein 1 (AP-1) transcription factor, one
of the potential downstream targets of activated JNK. RANK was found to
activate AP-1 in a manner dependent on the signaling molecules involved
in the JNK activation by this receptor. Furthermore, the activation of
JNK and ERK, but not that of p38, appeared to be involved in the AP-1
activation by RANK. Thus, RANK may use both JNK and ERK pathways to
signal to the AP-1 transcription factor.
| |
Introduction |
|---|
|
|
|---|
Receptor
activator of nuclear factor
B (RANK) is a recently cloned member of
the tumor necrosis factor receptor (TNFR) superfamily, showing 20 to
40% amino acid identity to other TNFR family proteins in its
extracellular domain (Anderson et al., 1997
). Several studies have
implicated physiological functions of this receptor in the regulation
of bone metabolism and the immune system. Stimulation of RANK with its
ligand, RANKL [also called ODF (osteoclast differentiation factor),
OPGL (osteoprotogerin ligand), and TRANCE (TNF-related activation
induced cytokine)], has been shown to induce the differentiation of
osteoclasts from hematopoietic progenitors and to deliver activating and survival signals in mature osteoclasts (Fuller et al., 1998
; Lacey
et al., 1998
; Yasuda et al., 1998
; Burgess et al., 1999
). The
RANKL/RANK interaction has been reported to increase the
allostimulatory activity of dendritic cells in a mixed lymphocyte
reaction and to provide the costimulation for T helper cell activation
in the absence of CD40, which was assumed to be mediated by enhanced dendritic cell function (Anderson et al., 1997
; Bachmann et al., 1999
).
The mechanism for the RANK-dependent increase of dendritic cell
function may be explained by the observation that RANKL/TRANCE up-regulated Bcl-xL expression and inhibited apoptosis of isolated dendritic cells (Wong et al., 1997
).
Many of the TNFR family members share certain biochemical consequences,
such as the activation of nuclear factor
B (NF-
B) and that of
c-Jun N-terminal kinase (JNK). In both of these events, direct or
indirect recruitment of TNF receptor-associated factor (TRAF) family
molecules to the receptor in the plasma membrane appears to be an
initial step. We and others have shown that RANK can directly associate
with TRAF proteins and activate NF-
B and JNK (Anderson et al., 1997
;
Darnay et al., 1998
; Wong et al., 1998
; Kim et al., 1999
).
The JNK activation pathway is a cascade of phosphorylation events that
involve JNK-activating kinases (JNKK1/SEK1/MKK4/MEK4 and JNKK2), which,
in turn, are activated by JNKK-activating kinases [MEKK1 and
MEKK5/apoptosis signal-regulating kinase 1 (ASK1)]. The JNK activation
cascade has been shown to be positively regulated by small GTPases Rac,
Cdc42, and Ras (Coso et al., 1995
; Minden et al., 1995
), and MEKK1 has
been demonstrated to bind those small GTPase proteins (Russell et al.,
1995
; Fanger et al., 1997
). In some cases, PI 3-kinase is implicated in
the Rac-mediated JNK activation (Timokhina et al., 1998
). MEKK1 and
ASK1 have been shown to participate in the TNF-induced or
TRAF2-mediated JNK activation (Liu et al., 1996
; Song et al., 1997
;
Nishitoh et al., 1998
). For the activation of JNK by TNF-
and CD40,
TRAF2 has been demonstrated to be essential (Lee et al., 1997
; Yeh et
al., 1997
). However, the role of TRAF proteins, JNK- and
JNKKK-activating kinases, small GTPases, and PI 3-kinase for the
RANK activation of JNK has not been studied to date.
JNK regulates gene expression by phosphorylating and thus activating
the transactivation domain of c-Jun in activator protein (AP)-1
complexes, homo- and heterodimers of Jun and Fos family proteins
(Derijard et al., 1994
). In addition to NF-
B activation, AP-1
activation appears to participate in the TNF regulation of gene
expression (Westwick et al., 1994
). However, AP-1 activation by other
TNFR family receptors, including RANK, has not been reported, and
whether AP-1 activation is a common feature of TNFR family proteins
that activate JNK has not been addressed. Because both the
rank and the c-fos genes seem to be essential for
osteoclast development and RANK can activate JNK, it was intriguing to
know whether the RANK signaling to JNK extends to AP-1 activation.
In this study, we determined the involvement of TRAF proteins, JNK-regulating kinases, small GTPases, and PI 3-kinase in the RANK-induced JNK activation and explored the potential linkage of JNK pathway to AP-1 in RANK signaling. The RANK-induced JNK activation appeared to be mediated by TRAF2 and to a less extent by TRAF6. The involvement of ASK1, MEKK1, NIK, and SEK1 was indicated, because the kinase-inactive mutants of these kinases showed dominant negative effects. The dominant negative mutants of small GTPases Rac and Ras, but not Rho, also attenuated RANK activation of JNK. In addition, RANK was found to cause AP-1 activation that seemed to be linked to JNK pathways, because the signaling molecule mutants with dominant negative effects on RANK activation of JNK also exerted inhibitory effects on AP-1 activation by RANK. Furthermore, the catalytic activities JNK and ERK, but not that of p38, was found to be required for the RANK induction of AP-1 activity.
| |
Materials and Methods |
|---|
|
|
|---|
Expression Plasmids.
Mammalian expression vectors for
T7-tagged human RANK, Flag-tagged TRAFs, GST-JNK1, and
GST-SEK-KR, and prokaryotic GST-c-Jun-77 constructs were
previously described (Kim et al., 1999
). Expression plasmids for
NIK-KK/AA429-430 and ASK1-KM were generous gifts
from Drs. H. Y. Song (Lilly Co. Center, Indianapolis, IN) and H. Ichijo (Tokyo Medical and Dental University, Tokyo, Japan),
respectively. MEKK-K432A (Xia et al., 1995
), JNK-APF (Derijard et al.,
1994
), ERK1-KR (Butch and Guan, 1996
), and ERK2-KR (Her et al., 1993
)
have been described. The dominant negative mutants Rac1-N17, RhoA-N19,
and Ras-N17 were kindly provided by Dr. J. S. Gutkind (National
Institutes of Health, Bethesda, MD) and have been described (Coso et
al., 1995
). The luciferase reporter constructs pAP1-Luc and
pNF-
B-Luc were from Dr. Y. D. Yun (Mogam Biotechnology Research
Institute, Yongin, Korea). N-terminal deletion mutant
TRAF2 (amino
acids 87-501) was kindly provided by Dr. H. Y. Song.
TRAF5
(amino acids 251-548) and
TRAF6 (amino acids 273-522) were
generated by polymerase chain reaction.
JNK Activity Assays.
293-EBNA cells (Invitrogen, San Diego,
CA) cultured in Dulbecco's modified Eagle's medium containing
10% fetal calf serum were plated into six-well plates (8 × 105/well). The next day, cells were transfected
with 0.3 to 0.5 µg of pEBG-JNK and other indicated DNAs plus 8 µl
of SuperFect reagent (Qiagen, Chatsworth, CA) following the
manufacturer's instruction. The total amounts of DNA were kept
constant by adding control vector DNAs. Twenty to 36 h after
transfection, cells were lysed in a lysis buffer (20 mM Tris-Cl, 150 mM
NaCl, 1% Triton X-100, 1 mM EDTA, 2 mM sodium orthovanadate, 50 mM
sodium fluoride, 2 µg/ml pepstatin A, 10 µg/ml aprotinin, 10 µg/ml leupeptin, pH 7.4) and centrifuged for 10 min at
10,000g. Cleared lysates (300 µg) were incubated with
glutathione beads for 2 h at 4°C. The precipitated beads were
extensively washed and subjected to kinase reactions as previously
described (Kim et al., 1998
).
RANK Ligand Stimulation.
RANKL stimulation was performed
using stable cell lines established by transfecting the full-length
human RANKL (pCEP4-RANKL) or the control (pCEP4) vector into 293-EBNA
and selecting cells in medium containing 250 µg/ml hygromycin and
G418. Cells were lysed in a hypotonic lysis buffer (10 mM Tris-HCl,
pH7.4, 60 mM KCl, 1 mM EDTA, 1 mM dithiothreitol, 1 mM sodium vanadate,
1 mM sodium fluoride, 10 µg/ml aprotinin, 10 µg/ml leupeptin, and 2 mM phenylmethylsulfonyl fluoride), and unbroken cells and nuclei were
removed by centrifugation for 5 min at 500g. The
supernatants were centrifuged for 10 min at 10,000g, and the
pellet fractions were used as crude membrane preparations to stimulate
RANK-transfected 293-EBNA cells. RANK stimulation was also carried out
with recombinant RANKL proteins immobilized on agarose beads. The
entire extracellular domain of RANKL was amplified by polymerase chain
reaction and subcloned into pET21a (Novagen, Madison, WI). The
transformed Escherichia coli were cultured and induced with
0.1 mM isopropyl
-D-thiogalactoside for
2 h at 37°C. Cell pellets were disrupted by sonication, and the
His-tagged RANKL was allowed to bind His·Bind resins (Novagen). The
beads were extensively washed and used for stimulation of cells.
Reporter Gene Assays.
Cells (1.5 × 105) were plated onto 24-well plates 1 day before
transfection with 100 to 200 ng of pAP1-Luc or pNF-
B-Luc and indicated amounts of various constructs, keeping the ratio of DNA:SuperFect reagent (Qiagen) at 1:2 or 1:3. Fifty nanograms of a
-gal vector was cotransfected for normalizing transfection efficiencies. The total amounts of DNA were kept constant by
supplementing with control vector DNAs. Sixteen to 20 h after
transfection, cells were lysed with 150 µl of Reporter Lysis Buffer
(Promega, Madison, WI), and 20 µl of lysates were used for
detection of luciferase activity with Luminometer (EG&G Berthold, Bad
Wildbad, Germany). In experiments with the p38 inhibitor SB
202190 (Calbiochem, San Diego, CA) and the PI 3-kinase inhibitor
wortmannin (Sigma, St. Louis, MO), cells were incubated with the
inhibitor 16 or 4 h after transfection for 2 to 16 h and
harvested at the time point of 20 to 24 h post-transfection.
Western Blotting Analyses.
Cell lysates were prepared as
above, resolved by SDS-polyacrylamide gel electrophoresis, and
transferred to a polyvinylidene difluoride membrane. The
membrane was blocked for 1 h in TBS-T (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20) plus 3% skim milk, incubated with anti-RANK,
anti-T7 (Novagen), anti-RANKL, anti-Flag M2 (Sigma), anti-GST, or
anti-hemagglutinin (12CA5), washed for 1 h in TBS-T, and
incubated with anti-mouse Ig- or anti-rabbit Ig-horseradish
peroxidase for 1 h. The immune complexes were detected by
the ECL system (Amersham). Generation of anti-RANK has been described
(Kim et al., 1999
), and anti-RANKL rabbit serum was generated by a
similar method using GST fusion proteins of the extracellular domain of
human RANKL as the immunogen.
| |
Results |
|---|
|
|
|---|
Induction of JNK Activity by RANK Expression in 293-EBNA
Cells.
To assess the signaling potential of RANK to the JNK
activation cascade, RANK was transiently transfected into human
embryonic kidney cells (293-EBNA), and JNK activity was evaluated. As
shown in Fig. 1A, an elevated level of
JNK activity was observed in the RANK-transfected cells. The
RANK-transfected cells showed further activation of JNK upon
stimulation with RANKL, presented on cell membranes (Fig. 1B, lane 2)
or immobilized on beads (lane 4), when compared with the levels of JNK
activity stimulated with the control membranes or beads (lanes 1 and
3). The RANKL-induced JNK activation was observed within 5 min and
reached a maximum at approximately 30 min (Fig. 1C). The expression of
RANKL in the membrane preparations used for stimulation of the
RANK-transfected cells was confirmed by Western blotting with
anti-RANKL sera raised against the extracellular domain of RANKL (Fig.
1D).
|
Inhibition of the RANK Activation of JNK by Dominant
Negative Mutants of TRAF2, TRAF6, ASK, MEKK, NIK, Rac, and Ras.
To
identify the signaling components involved in the RANK-induced JNK
activation, dominant negative mutant forms of signaling molecules that
have been implicated in JNK activation pathways for other receptors
were utilized. Studies with dominant negative TRAF2 (amino acids
87-501, lacking the N-terminal ring finger motif) in transgenic mice
and cultured cell line systems have indicated that TRAF2 is essential
for TNF-stimulated JNK activation (Lee et al., 1997
; Natoli et al.,
1997
). When the dominant negative TRAF2 was cotransfected with RANK,
the RANK-induced JNK activation was abolished (Fig.
2A, top). The TRAF6 mutant (amino acids
273-522), in which both the ring and zinc finger motifs are deleted,
also showed some inhibitory effect. The expression of the wild-type TRAF1, the TRAF member naturally lacking the ring finger motif, almost
completely inhibited the JNK activation by RANK. A dominant negative
TRAF5 (amino acids 251-548) had little effect, and the full-length
TRAF3 had a marginal effect (Fig. 2A, top). The lack of inhibitory
effect of TRAF5 mutant was not due to any defect of the plasmid,
because its expression was detected at a level similar to all other
TRAF plasmids used (Fig. 2A, bottom), and also the cotransfection of
the TRAF5 mutant resulted in the inhibition of RANK-induced NF-
B
activation (data not shown).
|
B and MEKK-SEK-JNK pathways, has been suggested, and
overexpression of NIK was shown to result in JNK activation (Karin and
Delhase, 1998
B under similar transfection conditions (data not
shown). The expression of NIK-KKAA429-430
significantly reduced the JNK activation by RANK (Fig. 2D, lane 6). PI
3-kinase has been shown to play a role in the JNK activation pathway
for receptor tyrosine kinases, perhaps through Rac (Logan et al., 1997Induction of AP-1 Activity by RANK and Involvement of TRAF
Proteins.
JNK activation has been linked to transactivation of the
AP-1 transcription complexes (Derijard et al., 1994
). The observation that RANK can stimulate JNK signaling pathways in which TRAF proteins, serine/threonine kinases, and GTP-binding proteins are involved prompted us to determine the AP-1-activating potential of RANK and to
evaluate the role of these signaling components. When overexpressed in
human embryonic kidney cells, RANK caused induction of an
AP-1-responsive reporter gene as efficiently as TRAF2 (Fig.
3A). This AP-1 activation by RANK
correlated with the amounts of transfected RANK DNA (Fig. 3B). We next
included N-terminal truncation mutants of TRAFs that have been shown to
have dominant negative effects on NF-
B activation. The TRAF2 and
TRAF5 mutants abolished the RANK-induction of AP-1 activity, and the
TRAF6 mutant had a significant inhibitory effect (Fig. 3C). In these
cells the TRAF mutants also inhibited RANK activation of NF-
B (Fig.
3D). In the absence of RANK, the TRAF6 deletion mutant itself exerted
some activation of AP-1, albeit to a lower extent than the wild-type
TRAF6 (data not shown). The cotransfection of wild-type TRAF1 or TRAF3
also resulted in reduction of the AP-1 activation by RANK (data not
shown).
|
Involvement of ASK1 and NIK in RANK-Induced AP-1 Activation.
To determine signaling components downstream of TRAF proteins in RANK
activation of AP-1, kinase-inactive mutants of ASK1, NIK, and MEKK1,
which all showed inhibitory effects on RANK stimulation of JNK
activity, were tested for the AP-1-derived reporter gene induction. As
shown in Fig. 4A, the kinase-null mutants
ASK1-KM and NIK-KKAA showed significant inhibitory effect on
RANK-induced AP-1 activation. The role of MEKK1 in AP-1 activation by
RANK could not be assessed, because transfection of the kinase domain mutant of MEKK1 itself evoked a high level of AP-1 activation under the
experimental conditions (data not shown). Transfection of various
amounts of ASK1-KM and NIK-KKAA showed dose-dependent inhibitory
effects (Fig. 4, B and C). The role of immediate upstream JNK kinase
SEK was also evaluated by using the kinase-inactive mutant SEK-KR that
was previously shown to inhibit RANK-induced JNK activation (Kim et
al., 1999
). The cotransfection of SEK-KR mutant resulted in suppression
of the AP-1 activation by RANK (Fig. 4D).
|
Differential Regulation of RANK Activation of AP-1 by MAPK Family
Enzymes.
The inhibitory effect of ASK1-KM and SEK1-KR on
RANK-induced AP-1 activation (Fig. 4, B and D) directed us to assess
the involvement of JNK in AP-1 activation of RANK. Two additional MAPK
family enzymes, ERK and p38, were also examined. As might be expected, cotransfection of JNK1-APF, a JNK1 mutant containing substitutions in
the TPY residues that are to be phosphorylated by upstream activating
kinases upon stimulatory signals, into 293-EBNA cells led to the
reduction in RANK-induction of AP-1 activity (Fig. 5A). In addition, kinase-inactive mutants
of ERKs were found to attenuate the AP-1 activation by RANK in these
cells, and the ERK2 mutant was more effective than the ERK1 mutant
(Fig. 5B). The ERK2-KR also efficiently suppressed the AP-1 activation
induced by NIK or TRAF6 (data not shown). The role of p38 MAPK family kinase was determined by treating RANK-transfected cells with a
specific p38 inhibitor SB202190. Treatment of the cells with the p38
inhibitor for 4 h had no effect on the RANK-induced AP-1 activation even at a dose 57-fold higher than the
IC50 (350 nM) (Fig. 5C). Variation in the
treatment time did not affect the result (data not shown). These
observations indicate that the RANK-to-AP-1 signaling pathway is
independent of p38 MAPK activity.
|
Inhibition of RANK Activation of AP-1 by Interference of Rac and
Ras but Not That of Rho and PI 3-Kinase.
We next evaluated the
role of Ras family of GTP-binding proteins and PI 3-kinase in the
RANK-induced AP-1 activation. The dominant negative mutant of Rac1,
RhoA, or Ras was cotransfected with RANK and AP-1-dependent reporter
gene, and the reporter activity was examined. Transfection of dominant
negative Rac1 and Ras resulted in reduction in the RANK activation of
AP-1 by 33 and 50%, respectively (Fig.
6A). In contrast, dominant negative RhoA
showed no inhibition under the same experimental conditions (Fig. 6A).
Treatment of cells with a specific PI 3-kinase inhibitor wortmannin
also did not inhibit the RANK activation of AP-1 at concentrations up
to 40-fold higher than IC50 (5 nM), which
suggested that the catalytic activity of PI 3-kinase is not involved in
RANK activation of the AP-1 transcription factor in these cells (Fig.
6B).
|
| |
Discussion |
|---|
|
|
|---|
Activation of JNK is one of the major biochemical consequences of
stimulation of TNF receptor family proteins such as TNFR1, TNFR2, CD95
(Fas/Apo-1), CD40, and CD27. For TNF-stimulation of JNK activity, TRAF2
seems to be essential, as demonstrated by studies with TRAF2 knock-out
and dominant negative TRAF2 transgenic mice (Lee et al., 1997
; Yeh et
al., 1997
), whereas Fas-induced JNK activation was shown to be mediated
by the Fas-binding protein Daxx (Yang et al., 1997
). Both TRAF2 and
TRAF5 were reported to be involved in CD27-induced JNK activation
(Akiba et al., 1998
; Gravestein et al., 1998
). In B cells, CD40
activation of JNK has been shown to be mediated by TRAF3 (Grammer et
al., 1998
). Recently, TRAF1 was implicated in prolonging TNF-induced
JNK activation (Schwenzer et al., 1999
). Overexpression of TRAF2, -5, or -6 could also evoke JNK activation in 293 cells (Song et al., 1997
).
Taken together different TRAF family proteins and perhaps complexes of
them may have capacity to transduce JNK activating signals from various
TNFR family members in different cellular environments. The role of
TRAF family proteins in RANK-induced JNK activation has not been
reported to date. In this study, we found that expression of N-terminal
deletion mutant of TRAF2, and to a lesser extent that of TRAF6,
inhibited RANK activation of JNK (Fig. 2A), implicating these TRAF
members in JNK activation by RANK. These TRAF proteins as well as
TRAF1,
3, and
5 were shown to associate with RANK in cultured cells
(Darnay et al., 1998
; Kim et al., 1999
), and N-terminal deletion
mutants of TRAF2, -5, and -6 have been demonstrated to have the
dominant negative effect on NF-
B activation (Wong et al., 1998
; Kim
1999
). However, the relative contribution of TRAF2 and TRAF6 to the
RANK-induced JNK and NF-
B activation pathways appears to be
different, because the dominant negative TRAF2 mutant was more
effective than the dominant negative TRAF6 in blocking JNK activation,
whereas with the same mutant constructs the reverse was observed in the
context of NF-
B activation by RANK under similar experimental
conditions (Figs. 2A and 3D).
Several MAPK cascade enzymes have been implicated in the signaling of
TNF family receptors to JNK. Some of these JNK-activating kinases have
been suggested to work immediately downstream of TRAF proteins. The
ASK1 and NIK proteins were shown to bind TRAF1, -2, -3, -5, and -6 and
the MEKK1 and GCK proteins to TRAF2 (Song et al., 1997
; Nishitoh et
al., 1998
; Yuasa et al., 1998
). All of these kinases were shown to
mediate JNK activation through TRAF2 for TNF or CD27 signaling (Akiba
et al., 1998
; Nishitoh et al., 1998
; Yuasa et al., 1998
). The
expression of kinase-inactive mutants of ASK1, MEKK1, or NIK inhibited
RANK-induced JNK activation (Fig. 2), suggesting that RANK could
engage, perhaps through TRAF2, these kinases for JNK pathway signaling.
MEKK1 has been shown to bind the JNK-activating small GTP-binding
proteins Rac, Cdc42, and Ras (Russell et al., 1995
; Fanger et al.,
1997
), which have been implicated in cytokine- and growth
factor-induced JNK activation (Coso et al., 1995
; Minden et al., 1995
).
In RANK signaling, Rac and Ras, but not Rho, seem to be involved,
because the dominant negative mutants of the former, but not the
latter, interfered RANK-induced JNK activation (Fig. 2D). Although PI
3-kinase has been implicated in the Rac-mediated JNK activation in some
cases (Timokhina et al., 1998
), the JNK activation by RANK appeared to
be independent of PI 3-kinase. Taken together, these results would
suggest that RANK signaling to JNK is mediated by
TRAF2-ASK1/MEKK1/NIK-SEK cascades with the TRAF2-to-ASK1/MEKK1/NIK
steps possibly being modulated by Rac and Ras. However, more questions,
such as the relative contributions of ASK1, MEKK1, and NIK, the
participation of other TRAF proteins in linking RANK to the kinases,
the immediate downstream target of NIK for JNK activation, and the
exact target of Rac and Ras in modulation of the RANK-to-JNK signaling,
remain to be addressed.
JNK regulates the AP-1 transcription factor by phosphorylating the
c-Jun component on Ser-63 and Ser-73 residues (Derijard et al., 1994
).
We found that RANK could evoke AP-1 transactivation, which was
regulated by TRAF2, ASK1, NIK, SEK1, Rac, and Ras, signaling components
involved in the RANK activation of JNK (Figs. 3, 4, and 6). The role of
NIK in the activation of JNK and AP-1 for TNF family receptors has not
been clearly resolved. In some studies, NIK appeared to have no effect
on TNF- and TRAF2-induced JNK activity (Song et al., 1997
; Karin and
Delhase, 1998
) and to cause AP-1 activation in JNK-independent manner
(Natoli et al., 1997
), whereas in other studies, NIK seemed to mediate
JNK activation by CD27 (Akiba et al., 1998
) and have JNK-activating
potential under high expression conditions (Karin and Delhase, 1998
).
The role of the JNK pathway in RANK-induced AP-1 activation was further
supported by the interference of the JNK-APF mutant, which is incapable of receiving activating signals (Fig. 5A). Another MAPK pathway also
seemed to participate in RANK activation of AP-1. The impedance of ERK,
but not that of p38, was found to affect AP-1 activation (Fig. 5, B and
C). ERK activity can positively regulate AP-1 by phosphorylating target
transcription factors. Phosphorylation of Elk-1 by ERK increases
formation of the ternary complex between Elk-1 and a homodimer of serum
response factor that binds the serum response element to
induce c-fos (Gille et al., 1995
), and the c-fos protein itself has
been shown to be stabilized upon phosphorylation by ERK (Okazaki and
Sagata, 1995
). ERK has been reported to be activated by CD40 through
TRAF6 (Kashiwada et al., 1998
). AP-1 activation through the
ERK-dependent pathway may also account for the inhibitory effect of
TRAF5 mutant on AP-1 activation (Fig. 3C) in the absence of an effect
on JNK activation by RANK (Fig. 2A). Whether RANK can activate ERK and
whether TRAF5 and TRAF6 are involved in that are under investigation.
Activation of Ras can lead to stimulation of both the ERK and JNK
subfamily enzymes of MAPKs (Minden et al., 1994
). The Ras stimulation
of ERK activity is mediated by the Ras-Raf-MEK pathway, whereas the JNK
activation signal from Ras seems to be transduced by the MEKK1-SEK
cascade. Ras may regulate the RANK induction of AP-1 through both JNK
and ERK pathways. This notion may be supported by the finding that the
dominant negative Ras was more effective than that of Rac in
attenuating the RANK activation of AP-1 (Fig. 3B), whereas both mutants
inhibited the RANK-induced JNK activation to the same extent (Fig. 2A).
Our results provide information based on which a potential mechanism
for signaling from RANK to JNK and to AP-1 is proposed (Fig.
7). It is postulated that RANK is linked
to redundant JNK-activating pathways through TRAF2 and possibly TRAF6.
The TRAF proteins can associate with ASK1, MEKK1, and NIK to activate
SEK, which, in turn, activates JNK. The small GTP-binding proteins Rac
and Ras regulate JNK and AP-1 activation, perhaps by modulating the
step at which TRAFs activate MAPKKKs. RANK also couples to ERK for AP-1
activation, although the pathway remains to be unraveled. For better
understanding of RANK signal transduction, further studies of the
signaling components involved in AP-1 activation through ERK and the
possibility of cross-talk between pathways for the activation of JNK,
ERK, and NF-
B will be required. Also, verification of the pathways
that have been identified to mediate RANK signaling using
overexpression systems under more normal conditions, such as in
dendritic cells or osteoclasts, will facilitate the linking of these
signaling pathways to physiological functions of RANK.
|
| |
Acknowledgments |
|---|
We thank Drs. H. Y. Song, Y. D. Yun, J. S. Gutkind, and H. Ichijo for constructs generously provided. We also thank Dr. H. Y. Song for encouragement and helpful discussions on experiments and Dr. J. G. Koland for critical comments and suggestions on this manuscript.
| |
Footnotes |
|---|
Received March 10, 2000; Accepted September 11, 2000
The authors acknowledge the financial support of the Korea Research Foundation made in the program year of 1998. S.H.L. was supported in part by research funds from Chosun University, 1997.
Send reprint requests to: Dr. Hong-Hee Kim, Department of Microbiology and Immunology, Chosun University Dental School, 375 Seosuk-Dong, Dong-Ku, Kwangju 501-759, South Korea. E-mail: hhkim{at}mail.chosun.ac.kr
| |
Abbreviations |
|---|
RANK, receptor activator of nuclear factor
B
(NF-
B);
RANKL, RANK ligand;
TNF, tumor necrosis factor;
TRAF, TNF
receptor-associated factor;
JNK, c-Jun N-terminal kinase;
AP-1, activator protein 1;
ASK1, apoptosis signal-regulating kinase 1;
ERK, extracellular signal-regulated kinase;
MAPK, mitogen-activated protein
kinase;
MEKK, MAPK/ERK kinase kinase;
NIK, NF-
B-inducing kinase;
SEK, SAPK (JNK)/ERK kinase;
GST, glutathione
S-transferase;
TNFR, tumor necrosis factor receptor;
PI, phosphatidylinositol;
TRANCE, TNF-related activation induced cytokine;
-gal,
-galactosidase.
| |
References |
|---|
|
|
|---|
B activation induced by TR8, an osteoclastogenic tumor necrosis factor receptor family member.
Arch Pharm Res
22:
454-458[Medline].
B activation and regulates proliferation and survival.
Immunity
7:
703-713[Medline].This article has been cited by other articles:
![]() |
X. Cheng, M. Kinosaki, M. Takami, Y. Choi, H. Zhang, and R. Murali Disabling of Receptor Activator of Nuclear Factor-{kappa}B (RANK) Receptor Complex by Novel Osteoprotegerin-like Peptidomimetics Restores Bone Loss in Vivo J. Biol. Chem., February 27, 2004; 279(9): 8269 - 8277. [Abstract] [Full Text] [PDF] |
||||
![]() |
D H. Jones, Y-Y Kong, and J M Penninger Role of RANKL and RANK in bone loss and arthritis Ann Rheum Dis, November 1, 2002; 61(90002): ii32 - 39. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. Shin, I. Kim, J. S. Lee, G. Y. Koh, Z. H. Lee, and H.-H. Kim A Novel Zinc Finger Protein That Inhibits Osteoclastogenesis and the Function of Tumor Necrosis Factor Receptor-associated Factor 6 J. Biol. Chem., March 1, 2002; 277(10): 8346 - 8353. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Lee, W. J. Chung, H. B. Kwak, C.-H. Chung, K. Kwack, Z. H. Lee, and H.-H. Kim Tumor Necrosis Factor-alpha Supports the Survival of Osteoclasts through the Activation of Akt and ERK J. Biol. Chem., December 21, 2001; 276(52): 49343 - 49349. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||